EU approval of Nycomed's new drug TachoSil expected in May  

The EU's scientific committee has recommended marketing authorisation for Nycomed's new drug for control of bleeding during operations

Pharmaceutical company Nycomed has successfully reached a milestone in the EU registration process of its new drug TachoSil, a product for control of bleeding during operations. The EU's scientific committee has recommended that the EU Commission issues EU marketing authorisation for TachoSil. The final decision from the commission is expected at the end of May 2004 so that Tachosil can be launched in Europe this year.


Håkan Björklund, CEO of Nycomed, says the expected launch of TachoSil is a cornerstone in the company's strategy to build closer relations with healthcare professionals in Europe. TachoSil is a medicated collagen sponge coated with coagulation factors designed to provide fast and effective control of bleeding during operations. Within minutes TachoSil seals and protects injured tissue to help reduce the risk of post-operative complications.


Nycomed is headquartered in Roskilde about 40 km west of Copenhagen. It is owned by three major capital funds headed by Credit Suisse First Boston. Nycomed employs about 2,800 people and has 36 sales office in 18 European markets. In addition the company's products are exported to countries such as the US and Japan. The news is reported by financial newspaper Børsen online and on Nycomed's website.


Link > Nycomed 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×